Sanofi to Take Stake in Cheplapharm in Swap for Drug Portfolio, Manufacturing Sites
By Adam Whittaker
Sanofi said it would give a portfolio of 20 developed medicines and three manufacturing sites to Cheplapharm in exchange for a 26.4% equity stake in the German pharmaceutical company.
The French drugmaker said Cheplapharm's expertise will ensure the so-called mature medicines continue to meet patients' needs over the next stage of drugs' lifecycle. The transfer should begin in the first quarter of 2027, Sanofi said.
Sanofi will then transfer the sites in Hungary, Singapore and France to Cheplapharm.
"Cheplapharm has been a trusted partner for more than a decade and this transaction significantly builds on its prior acquisitions from Sanofi's mature medicines portfolio," said Thomas Grenier, executive vice president of general medicines at Sanofi.
The full transaction is expected to be completed by the third quarter of 2027.
Write to Adam Whittaker at adam.whittaker@wsj.com
(END) Dow Jones Newswires
September 14, 2026 09:53 ET (13:53 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States